Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arctic Bioscience ASOSL:ABS 54 PS Ratio is 2.02 as of Jul. 17, 2026, which is 73% below its 10-year median of 7.61. GuruFocus rates OSL:ABS with a GF Score™ of 54/100 and a GF Value™ of kr10.68 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 930 Biotechnology companies, Arctic Bioscience AS ranks better than 84.62% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Arctic Bioscience AS's share price is kr3.00.
Arctic Bioscience AS's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was kr1.48. Hence, Arctic Bioscience AS's PS Ratio for today is 2.02.
The historical rank and industry rank for Arctic Bioscience AS's PS Ratio or its related term are showing as below:
OSL:ABS'
s PS Ratio Range Over the Past 10 Years
Min: 1.1 Med: 7.61 Max: 35.59
Current: 2.02
During the past 8 years, Arctic Bioscience AS's highest PS Ratio was 35.59. The lowest was 1.10. And the median was 7.61.
OSL:ABS's PS Ratio is ranked better than 84.62% of 930
companies
in the Biotechnology industry
Industry Median: 9.3
vs OSL:ABS: 2.02
Arctic Bioscience AS revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Arctic Bioscience AS was -13.40% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 2.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 14.60% per year.
During the past 8 years, Arctic Bioscience AS's highest 3-Year average Revenue per Share Growth Rate was 24.70% per year. The lowest was -4.80% per year. And the median was 4.20% per year.
Back to Basics: PS Ratio
Arctic Bioscience AS (OSL:ABS) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Arctic Bioscience AS PS Ratio Related Terms
Arctic Bioscience AS PS Ratio Historical Data
* Premium members only.
The historical data trend for Arctic Bioscience AS's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Arctic Bioscience AS's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arctic Bioscience AS PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arctic Bioscience AS's PS Ratio distribution charts can be found below:
* The bar in red indicates where Arctic Bioscience AS's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Arctic Bioscience AS's Share Price of today is kr3.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Arctic Bioscience AS's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was kr1.48.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Arctic Bioscience AS (OSL:ABS) has a PS Ratio of 2.02 as of Jul. 17, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Arctic Bioscience AS and its competitors. This is 73% below median its historical median of 7.61. Over the past decade, Arctic Bioscience AS's PS Ratio has ranged from 1.10 to 35.59. According to the industry distribution chart, Arctic Bioscience AS ranks #143 out of 930 companies in the Biotechnology industry, placing it in the top 15.4%.
Is Arctic Bioscience AS's PS Ratio too high?
Arctic Bioscience AS's current PS Ratio of 2.02 is 73% below median its 10-year median of 7.61. Over the past 10 years, this metric has ranged from a low of 1.10 to a high of 35.59. The Biotechnology industry median PS Ratio is 9.30. Arctic Bioscience AS's value of 2.02 is 78.3% below this industry median. Based on the distribution chart, Arctic Bioscience AS ranks #143 out of 930 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Arctic Bioscience AS has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Arctic Bioscience AS's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Arctic Bioscience AS ranks #143 out of 930 companies for PS Ratio. This places Arctic Bioscience AS in the top 15% of its industry — outperforming the majority of peers. The industry median PS Ratio is 9.30. Arctic Bioscience AS's value of 2.02 is 78.3% below this benchmark. Historically, Arctic Bioscience AS's own PS Ratio has ranged from 1.10 to 35.59 over the past decade. While the company's 10-year median is 7.61 vs. the industry median of 9.30, Arctic Bioscience AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.30, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arctic Bioscience AS's current PS Ratio of 2.02 is 78.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Arctic Bioscience AS and its competitors. For the Biotechnology industry, the median PS Ratio is 9.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arctic Bioscience AS's current PS Ratio is 2.02, which is 73% below median its own 10-year median of 7.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arctic Bioscience AS stock overvalued right now?
Based on GuruFocus' analysis, Arctic Bioscience AS (OSL:ABS) is currently considered Possible Value Trap. The stock's GF Value™ is kr10.68, compared to a current price of kr3.00 — trading 71.9% below its estimated fair value. The current PS Ratio is 2.02, which is 73% below median its 10-year median of 7.61 and 78.3% below the Biotechnology industry median of 9.30. Arctic Bioscience AS's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Arctic Bioscience AS (OSL:ABS), the current PS Ratio is 2.02 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arctic Bioscience AS (OSL:ABS) Overvalued in 2026?
Based on GuruFocus' analysis, Arctic Bioscience AS stock appears to be undervalued.
The current stock price of kr3.00 is trading 71.9% below its estimated GF Value™ of kr10.68.
GuruFocus considers Arctic Bioscience AS to be Possible Value Trap.
Key valuation signals for OSL:ABS:
PS Ratio: 2.02 (73% below median its 10-year median of 7.61)
GF Value™: kr10.68 vs. price of kr3.00 (71.9% below fair value)
Industry Position: 78.3% below the Biotechnology median (#143 of 930)
No single metric tells the full story. See the OSL:ABS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arctic Bioscience AS is a clinical-stage biotechnology company working to develop drug candidates within the areas of autoimmune and inflammatory diseases. It is developing pharmaceutical and commercializing nutraceutical products based on bioactive marine compounds, including lipids essential to maintaining cell membranes. The company's proprietary extraction technology is used to extract membrane fats from marine raw materials, such as herring roe and algae. Geographically, the company operates in Norway, the Americas, Europe, and APAC, with the majority of the revenue derived from the Americas.
54GF Score
Get the complete analysis for OSL:ABS
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:ABS has been successfully added to your 
